Editas Medicine, Inc. (EDIT) fundamentals score
Editas Medicine is a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 5.0 out of 10, Mixed fundamentals
- Growth: 7.3/10
- Profitability: 3.3/10
- Financial health: 4.4/10
- Earnings quality: 3.6/10
- Valuation: 6.2/10
Scores are calculated from Editas Medicine, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10